IVD Raw Material Market worth $31.1 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the IVD raw material market to grow from $21.5B in 2026 to $31.1B by 2031 (7.7% CAGR), led by antibodies with 34.5% share (2025). The report also highlights in-house manufacturing at 66.1% share (2025) and infectious disease testing as the largest application at 25.5% (2025). Growth tailwinds cited include rising infectious/chronic disease prevalence, increased early/accurate diagnostics demand, and expanding molecular diagnostics and point-of-care adoption, with Asia Pacific forecast to post the highest growth rate.

Analysis

The economic value in this theme accrues to the vendors that sit closest to assay design and revalidation, not the broad diagnostics platforms. That favors names with differentiated biologics content and switching costs, especially TECH and, to a lesser extent, MKKGY/TYOBY where local manufacturing and embedded customer relationships matter. The bigger structural implication is that in-house manufacturing dominance caps the addressable outsourced pool, so headline market growth will overstate the revenue lift for third-party suppliers unless they win design-ins.

The timing matters: this is a 2-4 quarter revenue conversion story, not an overnight rerate. Raw-material demand only becomes visible if new tests clear validation and procurement teams lock specifications; until then, the market is mostly buying a future TAM, not current orders. The main reversal risk is mix: if point-of-care adoption shifts toward ultra-low-cost formats or if hospitals delay inventory, pricing power can compress even as volumes rise.

Consensus is probably too optimistic on top-line pass-through and too pessimistic on mix/margin. The better read-through is that assay complexity and multiplexing increase the value per test for specialty reagents, while commodity components get competed away. That argues for owning the highest-value content suppliers on weakness, but not for chasing diversified life-science conglomerates where this theme is immaterial to earnings power.

Key Decisions for Investors

• Long TECH on pullbacks as the cleanest public proxy for differentiated diagnostics reagents; 3-6 month hold, with thesis invalidated if custom bioscience growth or gross margin trends decelerate next quarter.
• Relative-value pair: long TECH / short TMO at 1:1 notional to isolate reagent and antibody mix expansion versus a more diversified platform; best entered after an earnings call that confirms order conversion, not on the press-release itself.
• Treat MKKGY and TYOBY as watchlist names rather than active longs until we see evidence of Asia-Pacific share gains; liquidity and ADR volatility make them poor vehicles for a small TAM story.
• No chase trade in the broader diagnostics complex today; wait for upcoming company commentary on PoC and molecular diagnostics adoption, because the thesis fails if validation cycles or inventory digestion push demand into 2H rather than the next 1-2 quarters.